Latest Distribution Agreements News

icetana Limited reports its strongest quarterly annual recurring revenue growth in over four years, boosted by a landmark $3.6 million strategic partnership with SoftBank Robotics Group and expanding global deployments.

Nuchev Limited reports a record-breaking Q4 FY25 with revenues soaring 167% year-on-year, driven by strong growth across multiple markets and a strategic agency agreement in Australia.

RLF AgTech Ltd has closed FY2025 with a remarkable 74% increase in customer receipts and positive operating cash flow, underpinned by a comprehensive restructuring and renewed market momentum across Australia, China, and Asia.

Talius Group has reported a net profit of $0.37 million for Q2 2025, driven by a 6% increase in subscriptions and strategic partnerships that expand its market reach in aged care technology.

Lumos Diagnostics reported a 12% revenue increase for FY25 and inked a landmark US$317 million exclusive distribution deal for its FebriDx test, while advancing its FDA CLIA waiver application.

Lumos Diagnostics has locked in a A$5 million secured loan facility to support working capital as it advances toward FDA CLIA waiver for its FebriDx® test, complementing a landmark US distribution deal.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

CleanSpace Holdings reports a robust 26% increase in FY25 revenue, driven by strong growth across Europe, North America, and APAC regions, underscoring its expanding footprint in industrial respiratory protection.

Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.

HUB24 Limited has reported a record $19.8 billion in net inflows for FY25, driven by strong platform growth and significant migrations from Equity Trustees. The company also launched an innovative high net worth solution, reinforcing its market leadership.

Osteopore Limited has gained Swiss market approval for its 3D-printed bioresorbable implants under the EU Medical Device Regulation, completing its European product portfolio and strengthening its partnership with Zimmer Biomet.

Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.